These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34729841)

  • 1. Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia.
    Chaillon A; Bharat C; Stone J; Jones N; Degenhardt L; Larney S; Farrell M; Vickerman P; Hickman M; Martin NK; Bórquez A
    Addiction; 2022 May; 117(5):1338-1352. PubMed ID: 34729841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
    Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
    Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis.
    Stone J; Degenhardt L; Grebely J; Larney S; Altice FL; Smyrnov P; Rahimi-Movaghar A; Alavi M; Young AM; Havens JR; Miller WC; Hickman M; Vickerman P
    Lancet Psychiatry; 2021 Apr; 8(4):301-309. PubMed ID: 33640039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study.
    Degenhardt L; Larney S; Kimber J; Gisev N; Farrell M; Dobbins T; Weatherburn DJ; Gibson A; Mattick R; Butler T; Burns L
    Addiction; 2014 Aug; 109(8):1306-17. PubMed ID: 24612249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of incarceration and opioid agonist treatment transitions on risk of hospitalisation with injection drug use-associated bacterial infections: A self-controlled case series in New South Wales, Australia.
    Brothers TD; Lewer D; Jones N; Colledge-Frisby S; Bonn M; Wheeler A; Grebely J; Farrell M; Hickman M; Hayward A; Degenhardt L
    Int J Drug Policy; 2023 Dec; 122():104218. PubMed ID: 37813083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of opioid agonist treatment following release from prison in a cohort of men who injected drugs prior to imprisonment in Victoria, Australia: A discrete-time survival analysis.
    Curtis M; Dietze P; Wilkinson AL; Agius PA; Stewart AC; Cossar RD; Butler T; Walker S; Kirwan A; Winter RJ; Stoové M
    Drug Alcohol Depend; 2023 Jan; 242():109730. PubMed ID: 36516552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Connections program on return-to-custody, mortality and treatment uptake among people with a history of opioid use: Retrospective cohort study in an Australian prison system.
    Sullivan E; Zeki R; Ward S; Sherwood J; Remond M; Chang S; Kypri K; Brown J
    Addiction; 2024 Jan; 119(1):169-179. PubMed ID: 37726971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated effects of opioid agonist treatment in prison on all-cause mortality and overdose mortality in people released from prison in Norway: a prospective analysis of data from the Norwegian Prison Release Study (nPRIS).
    Bukten A; Stavseth MR
    Lancet Public Health; 2024 Jul; 9(7):e421-e431. PubMed ID: 38942554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of opioid dependence in New South Wales, Australia, 2014-16: Indirect estimation from multiple data sources using a Bayesian approach.
    Downing BC; Hickman M; Jones NR; Larney S; Sweeting MJ; Xu Y; Farrell M; Degenhardt L; Jones HE
    Addiction; 2023 Oct; 118(10):1994-2006. PubMed ID: 37292044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study.
    Marshall AD; Schroeder SE; Lafferty L; Drysdale K; Baldry E; Stoové M; Dietze P; Higgs P; Treloar C
    J Subst Use Addict Treat; 2023 Jul; 150():209066. PubMed ID: 37156422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study.
    Jones NR; Hickman M; Nielsen S; Larney S; Dobbins T; Ali R; Degenhardt L
    Drug Alcohol Depend; 2022 Jul; 236():109464. PubMed ID: 35523111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accessing opioid agonist treatment in prison in England and Scotland remains problematic - the views of people with lived experience.
    Webster R; Fearns C; Harriott P; Millar L; Simpson J; Wallace J; Wheatley M
    Int J Prison Health (2024); 2024 May; 20(2):143-155. PubMed ID: 38984599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001-2018: Findings from the OATS retrospective cohort study.
    Jones NR; Hickman M; Larney S; Nielsen S; Ali R; Murphy T; Dobbins T; Fiellin DA; Degenhardt L
    Drug Alcohol Depend; 2021 Jan; 218():108354. PubMed ID: 33121866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receipt of Opioid Agonist Treatment in provincial correctional facilities in British Columbia is associated with a reduced hazard of nonfatal overdose in the month following release.
    McLeod KE; Buxton JA; Karim ME; Martin RE; Nosyk B; Kurz M; Scow M; Felicella G; Slaunwhite AK
    PLoS One; 2024; 19(7):e0306075. PubMed ID: 38985687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
    Bozinoff N; DeBeck K; Milloy MJ; Nosova E; Fairbairn N; Wood E; Hayashi K
    Drug Alcohol Depend; 2018 Dec; 193():42-47. PubMed ID: 30340144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, Australia.
    Moradmand-Badie B; Tran L; Oikarainen N; Degenhardt L; Nielsen S; Roberts J; Ward S; Bowman J; Larney S
    Drug Alcohol Rev; 2021 Jan; 40(1):98-108. PubMed ID: 32808357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study.
    Larney S; Gisev N; Farrell M; Dobbins T; Burns L; Gibson A; Kimber J; Degenhardt L
    BMJ Open; 2014 Apr; 4(4):e004666. PubMed ID: 24694626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Punitive discontinuation of opioid agonist therapy during incarceration.
    Marmel A; Bozinoff N
    Int J Prison Health; 2020 Aug; 16(4):337-342. PubMed ID: 33634666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.